GlassScriptPhysician profile
Josh Parrish Buschling
NPI 1841654712
$2,737.11
in general payments reported to CMS, 2019-2025
25 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $74.55 · 2021: $313 · 2022: $427 · 2023: $515 · 2024: $608 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.57 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $566.05 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $339.17 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $176.43 | 2022-2025 | |
| Mylan Specialty L.P. | $151.52 | 2020-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.78 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $94.04 | 2022-2025 | |
| Abbvie INC. | $79.61 | 2023-2025 | Ubrelvy, Qulipta |
| Vanda Pharmaceuticals INC. | $61.52 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.56 | 2025 | Jardiance |
| Exact Sciences Corporation | $51.11 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $49.11 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $45.22 | 2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $37.34 | 2024 | Voquezna |
| Tactile Systems Technology INC | $35.74 | 2025 | Flexitouch Plus, Nimbl |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.35 | 2021 | |
| Optinose US, INC. | $23.30 | 2025 | |
| Amgen INC. | $22.51 | 2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $19.64 | 2022 | |
| Irhythm Technologies, INC. | $19.34 | 2023 | Zio Xt Patch |
| Philips North America LLC | $16.74 | 2023 | |
| Abbott Laboratories | $16.40 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $15.40 | 2024 | Veozah |
| Organogenesis INC. | $15.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Buschling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.